EN BMS launches India's first dual immunotherapy for metastatic melanoma Bristol Myers Squibb introduces RELOPDUO, India's first LAG-3 dual immunotherapy for metastatic melanoma, improving patient outcomes. 2 weeks, 4 days ago
EN
EN